2020 Yangtze River Delta In Vitro Diagnostics Industry Summit Officially Opens in Shanghai

The forum was moderated by Ms. Xu Meifang, Executive Deputy Director of the Shanghai Jiading Advanced Technology Innovation and Incubation Center. She introduced the background of the forum, the distinguished guests in attendance, and the collaborating organizations, and extended a warm welcome to all participants.

Xu Meifang

The opening ceremony featured welcome addresses by Mr. Li Jia, Director of the Biopharmaceutical Industry Division at the Shanghai Municipal Commission of Economy and Informatization, and Mr. Cai Ning, Director of the Jiading District Commission of Economy. Mr. Li Jia stated that in 2019, Shanghai’s biopharmaceutical output reached RMB 383.3 billion. The city is currently strengthening resource integration and pooling innovative resources to build a world-class biopharmaceutical industry cluster. Jiading District has gathered a number of outstanding biopharmaceutical enterprises. For the Jiading Industrial Park, efforts are being made to guide its specialized development, promote the integration of the biopharmaceutical industry, address existing weaknesses, and ensure the effective implementation of industrial policies. He also extended his best wishes for the complete success of this forum.

Li Jia

Mr. Cai Ning mentioned that Jiading, a renowned historical and cultural city in the Jiangnan region, is a major industrial hub in Shanghai, home to multiple industrial parks with output values exceeding RMB 100 billion each. The biomedical industry is also a key focus area for the Jiading District. With its favorable ecological environment, business-friendly climate, and talent attraction policies, Jiading aims to attract more high-tech biomedical enterprises to establish operations in the district.

Cai Ning

Following the opening remarks, Lei Wenlong, Deputy Secretary of the Party Working Committee and Deputy Director of the Administrative Committee of Jiading Industrial Zone in Shanghai, as well as Party Secretary and Chairman of the Group Company, introduced the biomedical industry in Jiading Industrial Zone. He pointed out that Jiading District is a key hub city in the Yangtze River Delta region. The Jiading Industrial Park has gathered approximately 200 biomedical enterprises, featuring a comprehensive and well-supported industrial chain. The innovative medical device industry chain has fostered close collaboration among industry, academia, and research institutions, accelerating industrial upgrading and development. Moreover, diversified support platforms have created a favorable and conducive environment for entrepreneurship, giving rise to more outstanding biomedical companies.

Lei Wenlong

At the main forum, Ms. Lu Yeqing, Member of the Party Working Committee of Shanghai Jiading Industrial Zone, Deputy Secretary of the Party Committee and General Manager of the Group Company, attended as a signing guest and completed the signing ceremony with 12 newly settled biomedical enterprises: Limu Scientific Instruments, Bai’an Ke Medical, Huayun Medicine, Yiwen Biology, Liujing Technology, Yiminokang Biology, Hanmian Protection, Hemai Biology, Huiyu Intelligence, Xindian Biology, Zeheng Metrology Testing, and Huikai Medical. She expressed her hope that the addition of these enterprises would accelerate the development of the biopharmaceutical industry in the industrial zone.

Signing Ceremony

Following the signing ceremony, the conference also held unveiling ceremonies for the Technology Transfer Base of the Institute of Translational Medicine at Shanghai University, the Yupei CDMO Medical Device Empowerment Platform, the R&D and Pilot Production Base for In Vitro Diagnostic Kits of Bioutils Mass Spectrometry, and the Biohuman Education and Training Base of Shanghai Chuyu Biotechnology Co., Ltd., which became a major highlight of this forum.

The representatives from each base are: Mr. Hu Honggang, Deputy Dean of the Institute of Translational Medicine at Shanghai University; Mr. Lou Ge’er, Co-founder of Shanghai Bioprofile Biomedical Technology Co., Ltd.; Ms. Sheng Yun, CEO of Yupei Medical Technology Co., Ltd.; and Mr. Xing Zhigang, CEO of Shanghai Chuyu Biotechnology Co., Ltd.

Mr. Ding Zhe, Deputy Secretary of the Party Committee of the Shanghai Jiading District Administration for Market Regulation, unveiled the plaque for the Technology Transfer Base of the Institute of Translational Medicine at Shanghai University; Mr. Wu Wenhua, Deputy Director of the Shanghai Jiading District Commission of Economy and Information Technology, unveiled the plaque for the Pilot Production Base for R&D of Biotech Mass Spectrometry In Vitro Diagnostic Kits; Mr. Tang Weimin, Deputy Head of the United Front Work Department of the CPC Shanghai Jiading District Committee, unveiled the plaque for the Yupei CDMO Medical Device Empowerment Platform; and Mr. Xu Wenzhong, Deputy Secretary of the Party Committee of the Shanghai Jiading District Health Commission, unveiled the plaque for the Biological Human Education and Training Base of Shanghai Chuyu Biotechnology Co., Ltd.

Unveiling Ceremony

During the keynote session, Professor Gao Hengjun, Professor of Internal Medicine at Tongji University and Director of the Shanghai National Engineering Research Center for Biochips; Mr. Chen Shaoxiong, Executive President and Secretary-General of the Shanghai Biopharmaceutical Industry Association; and Researcher Wang Yongming from the School of Life Sciences at Fudan University each delivered keynote addresses.

Professor Gao Hengjun delivered a keynote address titled “The Novel Clinical Translation CBDTM Model: Demonstrating Its Value in the Fight Against COVID-19,” set against the backdrop of the pandemic. Professor Gao stated that precision medicine encompasses predictive prevention, early screening and diagnosis, and personalized treatment. A key aspect lies in how the establishment of biobanks facilitates the translation of the molecular diagnostics industry, with biological sample resources constituting a major national strategic resource. The patient-sample-centric CBDTM model represents an innovative approach in biopharmaceuticals; during the early stages of the COVID-19 outbreak, it provided robust support for the development of nucleic acid testing reagents and for early epidemic prevention and control.

Gao Hengjun

President Chen Shaoxiong’s primary research focus is on the development strategy of the biopharmaceutical industry. He presented on the topic “Current Status and Countermeasures for Enhancing Shanghai’s Innovation Source Capacity in the Biopharmaceutical Sector.” During the conference, he noted that China has demonstrated particularly outstanding performance amid the continuous growth of the global biopharmaceutical market size. As a leading region in the Yangtze River Delta with international competitiveness in China’s biopharmaceutical industry, Shanghai is building a complete pharmaceutical industrial chain and assembling high-end professional platforms for the pharmaceutical sector. Although the industry faces pressures related to human resources, capital, and materials, new technologies are bringing new opportunities, and new business models are fostering emerging industries. Meeting the demand for smart healthcare under the paradigm of precision medicine is the key to achieving breakthroughs.

Chen Shaoxiong

Researcher Wang Yongming is primarily engaged in the development and application of gene editing technologies. Under the theme of “CRISPR-Based In Vitro Diagnostics Research,” he introduced the discovery and origins of CRISPR technology, the adaptive immune system of bacteria, and this year’s highly acclaimed Nobel Prize in Chemistry. He also noted that gene editing technologies have been applied in fields such as mammalian research, genetic testing, and gene therapy. Significant R&D efforts have been devoted to CRISPR-based in vitro diagnostic products; scientists have investigated challenges such as weak signals and low sensitivity, and the development of opvCRISPR technology has provided effective solutions to these issues.

Wang Yongming

This forum focuses on molecular diagnostics, microfluidics technology, metabolomics testing, clinical trials, the development of translational medicine bases, and patent commercialization. It provides the latest industry insights, showcases recent application advancements, and establishes a platform for collaboration and exchange among academia, industry, research institutions, and medical practitioners. Under the guidance of the Shanghai Municipal Commission of Economy and Informatization, the Organization Department of the CPC Shanghai Jiading District Committee, the Shanghai Jiading District Economic Commission, the Shanghai Jiading District Science and Technology Commission, the Shanghai Jiading District Health Commission, and the Management Committee of Shanghai Jiading Industrial Zone, the event is hosted by Shanghai Jiading Industrial Zone Development (Group) Co., Ltd., and organized by the Shanghai Jiading Advanced Technology Innovation and Incubation Center and Translational Medicine Network. It has received strong support from organizations such as the Shanghai Biopharmaceutical Industry Association and the Shanghai Jiading District Industrial Promotion Service Center.